4.7 Article

Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies

期刊

RHEUMATOLOGY
卷 61, 期 9, 页码 3677-3685

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keab931

关键词

systemic sclerosis; interstitial lung disease; immunosuppressant; outcome

资金

  1. Japanese Ministry of Health, Labour and Welfare

向作者/读者索取更多资源

This study aimed to investigate the benefits of early therapeutic intervention in patients with early SSc. The results showed that the early intervention group had a lower proportion of stable pulmonary function, a higher reduction in active disease, and significantly lower rates of clinical worsening compared to the delayed intervention group.
Objective To examine whether early therapeutic intervention, compared with delayed intervention, is beneficial for patients with early SSc. Methods This is a single-centre, retrospective cohort study of SSc patients who received CYC, MMF, MTX or tocilizumab for diffuse cutaneous SSc (dcSSc) or interstitial lung disease (ILD) within 6 years after disease onset. The patients were divided into early and delayed intervention groups based on the disease duration of <= 18 and >18 months at treatment introduction, respectively. Clinical worsening was defined as the development of any original or revised ACR Composite Response Index in SSc (CRISS) step 1 event or progressive fibrosing ILD (PF-ILD). Results There was no difference in baseline characteristics between the early (n = 25) and delayed (n = 21) intervention groups except forced vital capacity, which was better in the early vs delayed intervention groups. The early intervention group less frequently had stable pulmonary function over 1 year than did the late intervention group (odds ratio 0.087, 95% CI: 0.0079, 0.51; P = 0.003). The active disease was significantly decreased from 79% to 42% in the early intervention group (P = 0.007), but the change in the delayed intervention group was not statistically significant (68% to 42%; P = 0.11). Cumulative rates free from clinical worsening events defined by revised ACR-CRISS and PF-ILD were significantly higher in the early vs delayed intervention groups (P = 0.03 and 0.003, respectively). Conclusion A therapeutic 'window of opportunity' might exist in SSc patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据